Alla studier
Aktiv men inte rekryterandeOBSERVATIONELL

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

This study is designed to watch and understand how a treatment called Dupixent works for people with a type of eczema called atopic dermatitis. It's not a typical trial with new medicines, but rather an observation of how Dupixent is used in real life, after a doctor has already prescribed it for a patient. Researchers will collect information on patients' health history, how they use Dupixent, how effective it is over time, and any other allergic conditions they might have. They will also look at any side effects. This helps us understand the long-term benefits and safety of Dupixent when used by people aged 12 and older in their daily lives.

Överblick

Status
Aktiv men inte rekryterande
Sponsor
Regeneron Pharmaceuticals
Inskrivningsmål
858
Starta
06 Apr 2018
Beräknad slutförande
30 mars 2027

Vad handlar denna studie om?

This study is about a medicine called Dupixent, which is used to treat a type of eczema known as atopic dermatitis. Instead of testing a new drug, this study aims to learn about Dupixent's use in real life, after it has been prescribed by a doctor as part of your normal care. Think of it like a long-term survey, where researchers gather information from people who are already starting Dupixent treatment.

The main goals are to understand who uses Dupixent, how they use it (like how often or for how long), and how well it helps with their eczema over time. Researchers will also look at how Dupixent might affect other allergic conditions you might have, such as asthma or hay fever, and keep an eye on any side effects that might pop up during the treatment.

By collecting this information, doctors and researchers can get a clearer picture of how Dupixent works for a wide range of patients outside of strict clinical trial settings. This helps healthcare professionals and patients make more informed decisions about treating atopic dermatitis.

Viktiga punkter

  • This is an observation study, not a drug trial.
  • It helps us learn about Dupixent's long-term effects in real-world use.
  • You must be 12 years or older and newly starting Dupixent for eczema.
  • Participation involves sharing information about your health and treatment.
  • It aims to understand both effectiveness and safety over time.
  • Du kan sluta delta när som helst.

Vem kan vara berättigad?

You might be able to take part if you are 12 years old or older and are just starting treatment with Dupixent for your eczema (atopic dermatitis). You need to be willing to follow the study's instructions and fill out questionnaires about your health and treatment.

However, you won't be able to join if your doctor thinks you have a medical condition that would make it hard for you to take part fully, like a very short life expectancy or severe memory problems. Also, if you've used Dupixent in the last six months, you wouldn't be able to join this particular study. Only your doctor can tell you for sure if you meet all the requirements.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är du 12 år eller äldre?
  2. Are you just about to start Dupixent for your eczema?
  3. Can you understand and fill out questionnaires?
  4. Are you willing and able to attend study visits?
  5. Have you NOT used Dupixent in the last six months?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part, you will be observed as you receive Dupixent as prescribed by your doctor – it's not given as part of the study. You will have regular visits where researchers will record information about your health, how your eczema is doing, and how you're using Dupixent. You will also be asked to fill out questionnaires about your symptoms and experiences. The study aims to follow you over a long period to understand the long-term effects of Dupixent.

Potentiella risker och fördelar

Taking part in this study may offer the benefit of closely monitoring your treatment and contributing valuable information that could help others with eczema. As you are already receiving Dupixent, you wouldn't be exposed to new drug-related risks specifically from the study itself, beyond those already associated with your prescribed treatment. The main 'risk' is the time commitment for visits and questionnaires. Remember, you can choose to stop participating in the study at any time, for any reason, without it affecting your medical care.

Platser (99)

  • Regeneron Investigational Site
    Verifierat postnummer
    Birmingham, USA
  • Regeneron Investigational Site
    Verifierat postnummer
    Gilbert, USA
  • Regeneron Investigational Site
    Verifierat postnummer
    Fountain Valley, United States
  • Regeneron Investigational Site
    Verifierat postnummer
    Laguna Hills, USA
  • Regeneron Investigational Site
    Verifierat postnummer
    Loma Linda, USA
  • Regeneron Investigational Site
    Verifierat postnummer
    Los Angeles, USA
  • Regeneron Investigational Site
    Verifierat postnummer
    Los Angeles, USA
  • Regeneron Investigational Site
    Verifierat postnummer
    Manhattan Beach, United States
  • Regeneron Investigational Site
    Verifierat postnummer
    Newport Beach, USA
  • Regeneron Investigational Site
    Verifierat postnummer
    Oceanside, United States
  • Regeneron Investigational Site
    Verifierat postnummer
    Redondo Beach, United States
  • Regeneron Investigational Site
    Verifierat postnummer
    Riverside, United States

Vanliga frågor

Vad är huvudsyftet med denna studie?

The study aims to understand how Dupixent works for people with eczema in their daily lives, including how it's used, how effective it is, and any side effects over time.

Will I be given Dupixent as part of this study?

No, you will only be included if your doctor has already prescribed Dupixent for your eczema as part of your standard medical care, and you are just starting it.

Vem kan delta i denna studie?

You must be 12 years or older, starting Dupixent for eczema, and able to follow study instructions and complete questionnaires.

What will I need to do if I join?

You'll have your information collected at regular visits and fill out questionnaires about your health and Dupixent treatment. This will happen over a long period.

Can I stop being part of the study if I change my mind?

Yes, you can leave the study at any time, and it won't affect the medical care you receive from your doctor.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.